Issue 21, 2023
From the journal:

Chemical Science

In vivo biocompatibility of ZIF-8 for slow release via intranasal administration†

Sneha Kumari, ORCID logo *a   Thomas S. Howlett,a   Ryanne N. Ehrman,a   Shailendra Koirala,a   Orikeda Trashi,a   Ikeda Trashi,a   Yalini H. Wijesundaraa  and  Jeremiah J. Gassensmith ORCID logo *ab  

* Corresponding authors

a Department of Chemistry and Biochemistry, The University of Texas at Dallas, 800 West Campbell Rd., Richardson, TX 75080, USA
E-mail: Sneha.kumari@utdallas.edu, gassensmith@utdallas.edu

b Department of Biomedical Engineering, The University of Texas at Dallas, 800 West Campbell Rd., Richardson, TX 75080, USA

Abstract

Zeolitic imidazolate framework-8 (ZIF-8) is becoming popular in research for its potential in antigen protection and for providing a thermally stable, slow-release platform. While papers applying this material for immunological applications are aplenty in the literature, studies that explore the biosafety of ZIF-8 in mammals—especially when administered intranasally—are not well represented. We checked the body clearance of uncoated and ZIF-8-coated liposomes and observed that the release slowed as ZIF-8 is easily degraded by mucosal fluid in the nasal cavity. We delivered varying doses of ZIF-8, checked its short- and long-term effects on diagnostic proteins found in blood serum, and found no noticeable differences from the saline control group. We also studied their lung diffusing capacity and tissue morphology; neither showed significant changes in morphology or function.

Graphical abstract: In vivo biocompatibility of ZIF-8 for slow release via intranasal administration

About
Cited by
Related
Download options Please wait...

Supplementary files

Article information

DOI
https://doi.org/10.1039/D3SC00500C
Article type
Edge Article
Submitted
28 Jan 2023
Accepted
28 Apr 2023
First published
10 May 2023
This article is Open Access

All publication charges for this article have been paid for by the Royal Society of Chemistry
Creative Commons BY-NC license

Chem. Sci., 2023,14, 5774-5782

Permissions

Request permissions

In vivo biocompatibility of ZIF-8 for slow release via intranasal administration

S. Kumari, T. S. Howlett, R. N. Ehrman, S. Koirala, O. Trashi, I. Trashi, Y. H. Wijesundara and J. J. Gassensmith, Chem. Sci., 2023, 14, 5774 DOI: 10.1039/D3SC00500C

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements